Twist Bioscience Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Twist Bioscience Corp 公司

Twist Bioscience Corporation 是一家合成生物学和基因组学公司，该公司开发了脱氧核糖核酸 (DNA) 合成平台，以实现生物工程的工业化。该公司平台的核心是一种专有技术，专门通过在硅片上写入 DNA 来制造合成 DNA。该公司利用其技术制造各种基于合成 DNA 的产品，包括合成基因、下一代测序 (NGS) 制备工具和用于药物发现和开发的抗体库。其基因产品包括多路复用基因片段、表达基因、克隆基因和基因片段。该公司还生产合成核糖核酸 (RNA) 以及抗体蛋白。该公司还在 DNA 和生物药物发现的数字数据存储方面寻求长期机会。该公司生产的产品适用于许多行业，包括医疗保健、工业化学品、农业和学术研究。

公司简介

公司代码TWST

公司名称Twist Bioscience Corp

上市日期Oct 31, 2018

CEODr. Emily M. Leproust, Ph.D.

员工数量923

证券类型Ordinary Share

年结日Oct 31

公司地址681 Gateway Blvd.

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编94080

电话18007190671

网址https://www.twistbioscience.com/

公司代码TWST

上市日期Oct 31, 2018

CEODr. Emily M. Leproust, Ph.D.

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Emily M. Leproust, Ph.D.

Chairman of the Board, Chief Executive Officer

330.63K

-0.68%

Mr. Patrick John Finn, Ph.D.

President, Chief Operating Officer

108.58K

-4.43%

Mr. Keith L. Crandell

Independent Director

92.71K

+5.07%

Mr. Dennis Cho

Chief Legal Officer and Corporate Secretary

48.36K

-0.74%

Ms. Paula Green

Senior Vice President - Human Resources

44.30K

-1.97%

Mr. Nelson C. Chan

Independent Director

22.25K

+25.16%

Dr. Melissa A. Starovasnik, Ph.D.

Independent Director

15.81K

+39.44%

Mr. Jan Johannessen

Independent Director

12.60K

+55.04%

Mr. Adam Laponis

Chief Financial Officer

7.34K

-11.12%

Mr. Robert Werner

Chief Accounting Officer, Vice President

--

名称

名称/职务

职务

持股

持股变动

Dr. Emily M. Leproust, Ph.D.

Chairman of the Board, Chief Executive Officer

330.63K

-0.68%

Mr. Patrick John Finn, Ph.D.

President, Chief Operating Officer

108.58K

-4.43%

Mr. Keith L. Crandell

Independent Director

92.71K

+5.07%

Mr. Dennis Cho

Chief Legal Officer and Corporate Secretary

48.36K

-0.74%

Ms. Paula Green

Senior Vice President - Human Resources

44.30K

-1.97%

Mr. Nelson C. Chan

Independent Director

22.25K

+25.16%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

NGS tools

51.15M

55.12%

Synthetic genes

28.22M

30.41%

Antibody discovery

5.70M

6.14%

Oligo pools

4.71M

5.08%

DNA libraries

3.02M

3.25%

地区USD

名称

营收

占比

Americas

55.19M

59.48%

EMEA

30.64M

33.02%

APAC

6.96M

7.50%

业务

地区

业务USD

名称

营收

占比

NGS tools

51.15M

55.12%

Synthetic genes

28.22M

30.41%

Antibody discovery

5.70M

6.14%

Oligo pools

4.71M

5.08%

DNA libraries

3.02M

3.25%

股东统计

更新时间: 8月20日周三

持股股东

股东类型

持股股东

占比

ARK Investment Management LLC

10.60%

The Vanguard Group, Inc.

9.64%

Artisan Partners Limited Partnership

8.38%

BlackRock Institutional Trust Company, N.A.

8.05%

William Blair Investment Management, LLC

6.47%

其他

56.85%

持股股东

占比

ARK Investment Management LLC

10.60%

The Vanguard Group, Inc.

9.64%

Artisan Partners Limited Partnership

8.38%

BlackRock Institutional Trust Company, N.A.

8.05%

William Blair Investment Management, LLC

6.47%

其他

56.85%

股东类型

持股股东

占比

Investment Advisor

59.82%

Investment Advisor/Hedge Fund

36.44%

Hedge Fund

12.53%

Research Firm

5.06%

Individual Investor

1.94%

Pension Fund

1.48%

Bank and Trust

0.41%

Family Office

0.18%

Insurance Company

0.07%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

575

70.44M

116.72%

-302.44K

2025Q1

585

70.23M

117.22%

-1.63M

2024Q4

578

67.47M

113.11%

-8.03M

2024Q3

588

67.80M

115.74%

-8.48M

2024Q2

579

66.59M

114.39%

-10.53M

2024Q1

565

68.18M

117.94%

-8.61M

2023Q4

559

67.81M

117.39%

-11.70M

2023Q3

560

68.09M

118.66%

-11.36M

2023Q2

577

69.42M

121.49%

-5.07M

2023Q1

593

64.77M

113.93%

-4.20M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

ARK Investment Management LLC

6.24M

10.42%

-140.57K

-2.20%

Mar 31, 2025

The Vanguard Group, Inc.

5.85M

9.77%

+60.28K

+1.04%

Mar 31, 2025

Artisan Partners Limited Partnership

5.85M

9.77%

-42.31K

-0.72%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.63M

7.73%

+9.40K

+0.20%

Mar 31, 2025

William Blair Investment Management, LLC

3.81M

6.35%

+857.14K

+29.06%

Mar 31, 2025

State Street Global Advisors (US)

2.69M

4.5%

+149.68K

+5.88%

Mar 31, 2025

EdgePoint Investment Group Inc.

1.11M

1.86%

+1.11M

--

Mar 31, 2025

Amova Asset Management Co., Ltd.

2.42M

4.03%

-197.17K

-7.55%

Mar 31, 2025

Invesco Advisers, Inc.

3.34M

5.57%

-197.51K

-5.59%

Mar 31, 2025

Point72 Asset Management, L.P.

1.43M

2.39%

+1.43M

--

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

iShares Health Innovation Active ETF

0.2%

Hypatia Women CEO ETF

0.15%

ProShares Hedge Replication ETF

0.08%

First Trust NASDAQ BuyWrite Income ETF

0%

Vanguard US Momentum Factor ETF

0%

Invesco Dorsey Wright Healthcare Momentum ETF

0%

First Trust Long/Short Equity ETF

0%

First Trust NASDAQ Pharmaceuticals ETF

0%

First Trust Small Cap Core Alphadex Fund

0%

Invesco Dorsey Wright SmallCap Momentum ETF

0%

iShares Health Innovation Active ETF

占比0.2%

Hypatia Women CEO ETF

占比0.15%

ProShares Hedge Replication ETF

占比0.08%

First Trust NASDAQ BuyWrite Income ETF

占比0%

Vanguard US Momentum Factor ETF

占比0%

Invesco Dorsey Wright Healthcare Momentum ETF

占比0%

First Trust Long/Short Equity ETF

占比0%

First Trust NASDAQ Pharmaceuticals ETF

占比0%

First Trust Small Cap Core Alphadex Fund

占比0%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Twist Bioscience Corp

28.330USD

Twist Bioscience Corp

28.330

概览

公司

财务

分析